Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

BACKGROUND: Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC). The aim of this study was to evaluate the efficacy and safety of this regimen in combination with bevacizumab (BV), as first-line treatment for m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: García-Alfonso, P, Muñoz-Martin, A J, Alvarez-Suarez, S, Jerez-Gilarranz, Y, Riesco-Martinez, M, Khosravi, P, Martin, M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2010
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2990572/
https://ncbi.nlm.nih.gov/pubmed/20978503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605907
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia